Wealthfront Advisers LLC reported CLOVER HEALTH INVESTMENTS CO (CLOV) in 2 quarterly 13F filings from 2025 Q2 through 2025 Q3. The latest visible filing shows CLOV at 0.00% of the fund.
This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.
This page is designed to answer the real investor question behind a 13F filing: how meaningful was Wealthfront Advisers LLC's position in CLOVER HEALTH INVESTMENTS CO, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.
CLOV was reported at 0.00% of portfolio in the most recent visible filing.
Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.
Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.
Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.
As of 2025 Q4 β sorted by position size
These are the practical questions this page is built to answer before you even open the full history table.
Wealthfront Advisers LLC reported CLOV across 2 quarterly 13F filings, from 2025 Q2 through 2025 Q3.
The largest reported portfolio weight for CLOV was 0.00% in 2025 Q2.
The most recent filing on this page is 2025 Q3, when Wealthfront Advisers LLC reported 15,140 shares, equal to 0.00% of portfolio, with an estimated market value of $46K.
The chart compares Wealthfront Advisers LLC's quarterly CLOV portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.